97559-35-8 Usage
Uses
Used in Pharmaceutical Industry:
NEUROKININ A (4-10) is used as a target for drug development for the treatment of chronic pain and neurogenic inflammation. Its role in the transmission of pain signals and involvement in the immune response and inflammation make it a promising target for the development of new therapeutic agents.
Used in Research Applications:
NEUROKININ A (4-10) is used as a research tool to study the mechanisms of pain transmission, neurokinin receptor signaling, and the pathophysiology of chronic pain and neurogenic inflammation. It helps researchers understand the role of neurokinin A in various physiological processes and identify potential therapeutic targets for the treatment of related conditions.
Used in Diagnostic Applications:
NEUROKININ A (4-10) can be used as a biomarker for the diagnosis and monitoring of chronic pain and neurogenic inflammation. Its involvement in the pathophysiology of these conditions makes it a potential indicator of disease progression and response to treatment.
Check Digit Verification of cas no
The CAS Registry Mumber 97559-35-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,7,5,5 and 9 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 97559-35:
(7*9)+(6*7)+(5*5)+(4*5)+(3*9)+(2*3)+(1*5)=188
188 % 10 = 8
So 97559-35-8 is a valid CAS Registry Number.
InChI:InChI=1/C34H54N8O10S/c1-18(2)13-23(31(49)39-22(29(36)47)11-12-53-5)38-26(44)16-37-34(52)28(19(3)4)42-32(50)24(14-20-9-7-6-8-10-20)40-33(51)25(17-43)41-30(48)21(35)15-27(45)46/h6-10,18-19,21-25,28,43H,11-17,35H2,1-5H3,(H2,36,47)(H,37,52)(H,38,44)(H,39,49)(H,40,51)(H,41,48)(H,42,50)(H,45,46)/t21-,22-,23-,24-,25-,28-/m0/s1
97559-35-8Relevant academic research and scientific papers
Harbeson, Scott L.,Shatzer, Scott A.,Le, Tieu-Binh,Buck, Stephen H.
, p. 3949 - 3955 (1992)
Analogues of 10>NKA4-10 were synthesized in which each of the amide bonds was sequentially replaced with the reduced amide ψ(CH2NH) bond to determine the effect of this structural modification on the antagonism of NKA binding to
